Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,250.2	$ 1,573.8
Marketable securities	1,974.0	2,115.2
Accounts receivable, net	1,951.0	1,787.0
Due from anti-CD20 therapeutic programs	481.9	532.6
Inventory	931.7	902.7
Other current assets	843.3	962.0
Total current assets	7,432.1	7,873.3
Marketable securities	1,160.2	3,057.3
Property, plant and equipment, net	3,409.0	3,182.4
Intangible assets, net	3,661.3	3,879.6
Goodwill	5,170.3	4,632.5
Deferred tax assets	2,217.9	595.9
Investments and other assets	902.1	431.6
Total assets	23,952.9	23,652.6
Current liabilities:
Current portion of notes payable	0.0	3.2
Taxes payable	223.0	68.2
Accounts payable	295.7	395.5
Accrued expenses and other	2,633.7	2,901.3
Total current liabilities	3,152.4	3,368.2
Notes payable	5,928.4	5,935.0
Deferred tax liabilities	1,160.8	122.6
Other long-term liabilities	1,457.6	1,628.7
Total liabilities	11,699.2	11,054.5
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	97.8
Accumulated other comprehensive loss	(261.6)	(318.4)
Retained earnings	15,499.5	15,810.4
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	12,260.9	12,612.8
Noncontrolling interests	(7.2)	(14.7)
Total equity	12,253.7	12,598.1
Total liabilities and equity	$ 23,952.9	$ 23,652.6